In one study, KRAS mutation-activated PI3K/AKT/mTOR and AXL signaling contributed to pancreatic cancer cell resistance to MEK (a KRAS effector) inhibitors (Pettazzoni et al., 2015). This evidence concerns the gene MAP2K7 and pancreatic neoplasm.